Clinical Trials

46 enrolled

Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

NCT06788990 2026-03-23

FORTIFI-HN01

650 enrolled

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

NCT04613596 2026-03-18

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

806 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06236438 2026-02-23

LIVIGNO-4

840 enrolled

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

420 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT04619797 2026-02-03

SKYSCRAPER-06

542 enrolled

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06984588 2026-01-30

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

450 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07365319 2026-01-26

TeLuRide-008

750 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

720 enrolled

Squamous NSCLC

NCT06697301 2025-11-12

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

740 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04887870 2025-10-10

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

52 enrolled

Advanced or Metastatic Solid Malignancies

NCT06624644 2025-09-10

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Phase 2/3 Active not recruiting

135 enrolled

Dermatologic

Melanoma

NCT06082167 2025-08-17

STELLAR-305

600 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06513884 2025-06-22

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Phase 2/3 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

700 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04969861 2023-01-12

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Phase 2/3 Terminated

1 enrolled 6 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05429697 2022-09-27

Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

128 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT01905657 2021-10-06

MK-3475-010

1,034 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

700 enrolled